Understanding NCI: Toll-Free Teleconference Series
“Cancer Chemoprevention: A Discussion of Benefits and Risks”
The National Cancer Institute (NCI) invites you to participate in a teleconference this Tuesday, December 5, 2006 from 1:00 p.m. to 2:00 p.m. (EST) to learn more about cancer chemoprevention and how it impacts patient advocates.
NCI’s Dr. Worta McCaskill-Stevens will lead a distinguished panel of experts. A question and answer session for participants will follow the panelists’ remarks. In advance of the teleconference, learn more about cancer chemoprevention, by visiting: http://www.cancer.gov/prevention/
Topics include:
Þ Development of Chemoprevention for Breast Cancer from Treatment Trials
Þ Risks and Benefits of Chemoprevention of Breast & Prostate Cancer
Þ Chemoprevention Clinical Research: An Advocate’s Perspective
Þ Comparison of Risks and Benefits
Date: Tuesday, December 5, 2006 at 1:00 p.m. (EST)
Toll-Free: 1-800-857-6584 The call is toll-free and no registration is required.
Passcode: PREVENT
Toll-Free Playback: 1-866-498-5444 until January 5, 2007
Please join Dr. Worta McCaskill-Stevens, Medical Oncologist and Program Director of the NCI Division of Cancer Prevention; Dr. Larry Wickerham, Associate Chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP); Dr. Victor Vogel, Director of Magee Women’s Breast Cancer Program at the University of Pittsburgh; Dr. Howard Parnes, Chief of the Prostate and Urologic Cancer, NCI Division of Cancer Prevention; Ms. Ann Marie Gugger, a patient advocate who serves on the Participant Advisory Board of the National Surgical Adjuvant Breast and Bowel Project (NSABP); Mr. Julius Jones, patient advocate who is involved with the Prostate Cancer Prevention Trial (PCPT) and SELECT National Patient Advisory Board (NPAB); and Dr. Leslie Ford, Associate Clinical Director of the NCI Division of Cancer Prevention.